Capital Research Global Investors Has $147.61 Million Stock Holdings in iRhythm Technologies, Inc. (NASDAQ:IRTC)

Capital Research Global Investors lessened its stake in iRhythm Technologies, Inc. (NASDAQ:IRTC - Free Report) by 16.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,637,026 shares of the company's stock after selling 317,974 shares during the period. Capital Research Global Investors owned about 5.23% of iRhythm Technologies worth $147,611,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in shares of iRhythm Technologies during the 4th quarter valued at about $45,000. Van ECK Associates Corp increased its holdings in shares of iRhythm Technologies by 41.3% during the fourth quarter. Van ECK Associates Corp now owns 554 shares of the company's stock worth $50,000 after buying an additional 162 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of iRhythm Technologies by 166.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,037 shares of the company's stock valued at $94,000 after acquiring an additional 648 shares during the last quarter. KBC Group NV boosted its holdings in shares of iRhythm Technologies by 45.1% in the 4th quarter. KBC Group NV now owns 1,319 shares of the company's stock worth $119,000 after acquiring an additional 410 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in iRhythm Technologies during the 3rd quarter worth approximately $119,000.

Wall Street Analyst Weigh In

A number of research firms have commented on IRTC. The Goldman Sachs Group boosted their price objective on iRhythm Technologies from $91.00 to $124.00 and gave the stock a "neutral" rating in a research note on Monday, February 24th. Truist Financial increased their price objective on shares of iRhythm Technologies from $111.00 to $145.00 and gave the stock a "buy" rating in a report on Friday, February 21st. StockNews.com raised shares of iRhythm Technologies from a "sell" rating to a "hold" rating in a research note on Monday, February 24th. Needham & Company LLC increased their price target on shares of iRhythm Technologies from $125.00 to $138.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Finally, Wells Fargo & Company boosted their price objective on shares of iRhythm Technologies from $86.00 to $104.00 and gave the stock an "equal weight" rating in a research report on Friday, February 21st. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, iRhythm Technologies has an average rating of "Moderate Buy" and a consensus target price of $119.73.

iRhythm Technologies Trading Up 2.1 %

Shares of IRTC stock traded up $2.14 on Thursday, reaching $104.78. The company had a trading volume of 236,053 shares, compared to its average volume of 459,607. The stock has a market cap of $3.34 billion, a PE ratio of -28.79 and a beta of 1.45. The company has a 50-day moving average of $104.76 and a 200-day moving average of $93.96. The company has a current ratio of 6.27, a quick ratio of 6.12 and a debt-to-equity ratio of 9.00. iRhythm Technologies, Inc. has a 12 month low of $55.92 and a 12 month high of $128.52.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.30. The business had revenue of $164.33 million for the quarter, compared to the consensus estimate of $158.30 million. iRhythm Technologies had a negative return on equity of 118.83% and a negative net margin of 19.14%. On average, equities analysts forecast that iRhythm Technologies, Inc. will post -1.98 earnings per share for the current year.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.